GALECTIN THERAPEUTICS INC
GALT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for GALT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GALT
Galectin Therapeutics is a clinical-stage biopharmaceutical company developing therapies for fibrotic disease, cancer, and other conditions based on targeting galectin proteins, with its lead candidate belapectin (GR-MD-02) having completed a Phase 2b/3 trial in NASH cirrhosis that was terminated.
Key risk: Clinical trial failure
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 2 clinical trials for GALECTIN THERAPEUTICS INC.
Galectin Therapeutics is a clinical-stage biopharmaceutical company developing therapies for fibrotic disease, cancer, and other conditions based on targeting galectin proteins, with its lead candidate belapectin (GR-MD-02) having completed a Phase 2b/3 trial in NASH cirrhosis that was terminated.
- Galectin Therapeutics is a clinical-stage biopharmaceutical company focused on drug research and development for fibrotic disease, cancer, and selected other diseases, using galectin protein targeting [sec_mda · as of 2026-03-31].
- The company's lead drug candidate, belapectin (GR-MD-02), is a proprietary complex carbohydrate derived from naturally occurring plant products [sec_mda · as of 2026-03-31].
- A Phase 2b/3 clinical trial (NAVIGATE, NCT04365868) for belapectin in NASH cirrhosis was terminated [catalyst].
- As of 2026-06-30, the company reported cash and equivalents of $13.3M, a net loss of $9.1M, and negative shareholders' equity of $127.9M [sec].
- The company faces risks including inability to demonstrate efficacy in human trials, extensive FDA regulation, and limited trading volume [sec_mda · as of 2026-08-14].
What works
- Belapectin has completed a pharmacokinetic study in subjects with hepatic impairment (NCT04332432), which became fully enrolled in February 2022 and reported favorable results in 2023 [sec_mda · as of 2026-08-14].
- The company leverages established relationships with outside sources for preclinical models, toxicology, clinical trial operations, and manufacturing to achieve cost-effective drug development [sec_mda · as of 2026-08-14].
- Galectin's technology uses naturally occurring, readily-available plant products as starting material, which may provide a scalable manufacturing advantage [sec_mda · as of 2026-03-31].
What to weigh
- The company's Phase 2b/3 NAVIGATE trial for belapectin in NASH cirrhosis was terminated, raising uncertainty about the drug's clinical path [catalyst].
- As of 2026-06-30, the company had negative shareholders' equity of $127.9M and a net loss of $9.1M, indicating a weak financial position [sec].
- The company is subject to extensive and costly FDA regulation and may be unable to demonstrate the efficacy and safety of its product candidates in human trials [sec_mda · as of 2026-08-14].
- Limited trading volume and concentration of stock ownership are noted risks that could affect liquidity and stock price [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
Galectin is a clinical-stage biopharmaceutical company targeting galectin proteins for fibrotic disease and cancer.
“We are a clinical stage biopharmaceutical company engaged in drug research and development to create new therapies for fibrotic disease, cancer and selected other diseases. Our drug candidates are based on our method of targeting galectin proteins, which are key mediators of biologic and pathologic functions.”
SEC MD&A · March 31, 2026
Belapectin is a proprietary complex carbohydrate derived from plant products.
“We use naturally occurring, readily-available plant products as starting material in manufacturing processes to create proprietary, patented complex carbohydrates with specific mole”
SEC MD&A · March 31, 2026
The NAVIGATE Phase 2b/3 trial was terminated.
“Phase 3 Topline: A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, Interna - NCT: NCT04365868. Status: Terminated.”
Catalysts
Catalyst timeline
- 2020-06-16 · Phase 1 Start: A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal He — This study (NCT04332432) was completed and reported favorable results in 2023, but no new catalysts are listed beyond this.
- 2025-03-31 · Earnings: Earnings Report - SEC 8-K filing — This is a past earnings event; no future catalyst dates are provided.
- 2025-04-10 · Phase 3 Topline: A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, Interna — This trial (NCT04365868) was terminated, so no future topline results are expected.
Risks & what to watch (4)›
Key risks
- Clinical trial failure — The Phase 2b/3 NAVIGATE trial for belapectin was terminated, casting doubt on the drug's future [catalyst].
- Negative equity and losses — As of 2026-06-30, shareholders' equity was -$127.9M and net loss was $9.1M, indicating financial distress [sec].
- Regulatory and efficacy risks — The company may be unable to demonstrate efficacy in human trials and is subject to extensive FDA regulation [sec_mda · as of 2026-08-14].
- Low liquidity and ownership concentration — Limited trading volume and concentrated stock ownership are noted risks [sec_mda · as of 2026-08-14].
What to watch
- Any updates on belapectin's clinical development path following the termination of the NAVIGATE trial [catalyst].
- The company's ability to raise additional capital given its negative equity and cash burn [sec].
- Potential strategic partnerships or licensing deals that could provide funding or development support [sec_mda · as of 2026-08-14].
- Regulatory decisions or feedback from the FDA regarding belapectin's future [sec_mda · as of 2026-08-14].
Sources: Catalysts · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run GALECTIN THERAPEUTICS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available GALECTIN THERAPEUTICS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
16.8 months
OCF -$2M · Net income -$9M
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
0 buys · 8 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
99
Total value held
$45.8M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 3,933,084 | $11.0M |
| marshall wace, llp | 1,219,912 | $3.4M |
| osaic holdings, inc. | 1,122,670 | $3.1M |
| susquehanna international group, llp | 1,073,202 | $3.0M |
| great point partners llc | 800,000 | $2.2M |
| blackrock, inc. | 799,237 | $2.2M |
| millennium management llc | 798,434 | $2.2M |
| geode capital management, llc | 612,786 | $1.7M |
| two sigma investments, lp | 467,063 | $1.3M |
| commonwealth equity services, llc | 367,113 | $1.0M |
Showing top 10 of 99 institutional holders of GALECTIN THERAPEUTICS INC. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 17.6%
- Days to cover
- 21.9
- Shares short
- 7,388,749
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GALT short interestGovernance
Frequently asked questions
What is the AI investment thesis for GALECTIN THERAPEUTICS INC?
Galectin Therapeutics is a clinical-stage biopharmaceutical company developing therapies for fibrotic disease, cancer, and other conditions based on targeting galectin proteins, with its lead candidate belapectin (GR-MD-02) having completed a Phase 2b/3 trial in NASH cirrhosis that was terminated.
What is GALECTIN THERAPEUTICS INC's lead drug candidate?
GALECTIN THERAPEUTICS INC's most advanced tracked candidate is belapectin (Phase 1) for Hepatic Impairment; Prevention of Esophageal Varices.
Who is the CEO of GALECTIN THERAPEUTICS INC?
Mr. Joel Lewis CPA is the chief executive officer of GALECTIN THERAPEUTICS INC (GALT).
Where is GALECTIN THERAPEUTICS INC headquartered?
GALECTIN THERAPEUTICS INC (GALT) is headquartered in Norcross, GA, United States.
What therapeutic areas does GALECTIN THERAPEUTICS INC focus on?
GALECTIN THERAPEUTICS INC develops therapies across Oncology, Infectious Disease, Metabolic, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.